Pfizer Reports Five-Year PALOMA-3 Data for Ibrance in HR-Positive Breast Cancer

Pfizer today presented five-year overall survival data from the Phase 3 PALOMA-3 trial evaluating Ibrance (palbociclib) plus fulvestrant versus fulvestrant alone in patients with HR-positive, HER2-negative advanced breast cancer who had progressed on prior endocrine therapy. The data showed a clinically meaningful improvement in overall survival with Ibrance.